Researchers at the University of Pennsylvania have conducted a clinical trial, indicating that sorafenib (Nexavar), already used for advanced kidney and liver cancers, may also be beneficial in patients afflicted with thyroid cancer.
According to the study, sorafenib, taken in pill form, "nearly doubled the length of time that patients remained progression-free, from about six months to 11 months." While these findings are not indicative of a cure, Dr. Marcia Brose, lead researcher in the study, says that this does offer hope for this highly curable cancer, diagnosed in 60,000 Americans each year.
To read more about this study, which was presented on Sunday, June 2, 2013 at the annual meeting of the American Society of Clinical Oncology in Chicago, click here
No comments:
Post a Comment